This study investigates the safety and how well an investigational medication works when combined with chemotherapy.
The study evaluates the investigational medication's safety and effectiveness. It focuses on how well the medication works with chemotherapy for people who have not been treated before.
- Who can participate: Adults with confirmed metastatic pancreatic cancer who have not had prior systemic treatment for it can participate. They must have an ECOG performance status of 0-1 and adequate organ function.
- Study details: Participants will receive the investigational medication along with chemotherapy. Some will receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
- Study timelines: The study will last up to 2 years.